A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.

EBioMedicine · 2021 · PMC8054140 · PMID 33862582

Europe PMC DOI

hedged sentence

0.2090

closest p · 4.2× alpha

0.2090

boldest claim

The sentences

showed a trendp = 0.209not close (p > 0.1)

At the same time, SMAD4 alt patients showed a trend towards longer OS when treated with GemErlo compared to gemcitabine alone without reaching significance (log rank: DFS: p = 0.209, OS: p = 0.056).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.